Vertex Pharmaceuticals announced the first accepted medical presentations of the Phase 3 data on the investigational once ...
Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an ...
With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...
Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans ...
Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...
Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...
U.S. News' panel of financial advisors addresses the No. 1 issue on investors' minds in the back half of 2024.
Zacks.com on MSN23h
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback